Quality of Life Assessment: Key Issues in the 1990sS.R. Walker, Rachel M. Rosser Springer Science & Business Media, 2012 M12 6 - 487 pages It was over five years ago that the Centre for Medicines Research organized a workshop entitled "Quality of Life: Assessment and Application". This workshop brought together a unique group of participants, some of whom had been involved in studies on quality of life for well over a decade, whilst others were meeting the subject for the first time. This blend of experienced researchers and enthusiastic newcomers was a great stimulus to the discus sions which followed individual presentations as well as that resulting from the study groups. In the ensuing publication, a balance was sought between a consideration of the complex principles underlying the assessment of quality of life and the application of such assessments to specific clinical conditions which necessitated this approach. The organization in 1991 of a second workshop entitled "Quality of Life Assessment: Key Issues in the 1990s" resulted in a further consideration of the quality of life philosophy, concepts and key instruments together with an update on assessing quality of life in a number of major disease areas. Of particular importance was an examination of various viewpoints concerned with ethical questions and their implications, and quality oflife from industry, regulatory and health care purchasers' perspectives. As a result of this second workshop, the editors of the original book referred to above decided to produce a second edition with a number of updates and additional chapters. |
From inside the book
Page ix
... drugs were , so to say , in the book , but since then medicines have been developed with an eye to the uniformity of dose that could be used in the formulation . Currently , predictive science is coming to assessments of the quality of ...
... drugs were , so to say , in the book , but since then medicines have been developed with an eye to the uniformity of dose that could be used in the formulation . Currently , predictive science is coming to assessments of the quality of ...
Page xiii
... Drugs Group at the Unites States Food and Drug Administration . His responsibilities include evaluation of applications for testing and marketing of drugs for the treatment and prevention of cancer . His research interests are ...
... Drugs Group at the Unites States Food and Drug Administration . His responsibilities include evaluation of applications for testing and marketing of drugs for the treatment and prevention of cancer . His research interests are ...
Page xiv
... drug discovery company until 1991. Dr Read trained as an internist at the Peter Bent Brigham Hospital in Boston and held appointments in the Departments of Medicine and Surgery at the New England Deaconess Hospital , Harvard School of ...
... drug discovery company until 1991. Dr Read trained as an internist at the Peter Bent Brigham Hospital in Boston and held appointments in the Departments of Medicine and Surgery at the New England Deaconess Hospital , Harvard School of ...
Page xv
... drug information data . Professor P Selby , MA , MD , FRCP has been Professor of Cancer Medicine and Director of the Institute for Cancer Studies at the University of Leeds since June 1988 and a Consultant Physician at St James ...
... drug information data . Professor P Selby , MA , MD , FRCP has been Professor of Cancer Medicine and Director of the Institute for Cancer Studies at the University of Leeds since June 1988 and a Consultant Physician at St James ...
Page xvi
... drug research and development , an examination of the impact of international medicines regulations and policy issues on drug development , and investigating the role as well as the predictive value of pre - clinical animal toxicology ...
... drug research and development , an examination of the impact of international medicines regulations and policy issues on drug development , and investigating the role as well as the predictive value of pre - clinical animal toxicology ...
Contents
11 | |
rationale for a single | 65 |
Development testing and use of the Sickness Impact | 95 |
The Nottingham Health Profile | 111 |
an update | 131 |
A health index and output measure | 151 |
A fifteendimensional measure of healthrelated quality | 185 |
The EuroQol quality of life project | 197 |
Measurement of healthrelated quality of life in asthma | 301 |
Measuring quality of life in hypertension | 321 |
Measuring the quality of life of patients with angina | 333 |
Measuring quality of life in psychiatry | 343 |
Measuring the quality of life of patients with skin disease | 355 |
Ethical questions and their implication for QOL studies | 373 |
Industry perspectives on quality of life | 383 |
A regulatory view | 393 |
Indices versus profiles advantages and disadvantages | 209 |
The OnLine Guide to QualityofLife Assessment | 221 |
Measuring the quality of life of patients with cancer | 235 |
Measuring the quality of life of patients with rheumatoid | 269 |
Measuring the quality of life of patients with Parkinsons | 289 |
The cost effectiveness of pharmaceuticals | 401 |
Requirements for health care purchasers | 413 |
The importance of quality of life in policy decisions | 427 |
Appendices | 441 |
Other editions - View all
Quality of Life Assessment: Key Issues in the 1990s S R Walker,Rachel M Rosser No preview available - 1992 |
Quality of Life Assessment: Key Issues in the 1990s S.R. Walker,Rachel M. Rosser No preview available - 2012 |
Common terms and phrases
ACE inhibitors activities airways disease analysis angina antihypertensive application areas aspects Assessment of Quality asthma atenolol auranofin behaviour benefits cancer patients captopril chronic cilazapril clinical trials clinician compared comparison components concepts coronary correlation cost depression dimensions disability distress domains drug dysfunction effects evaluation example factors function scores groups health services health status measures health-related quality hospital hypertension illness impairment important improvement indicators individual instrument interventions interview investigator Kaplan levodopa measure of health measurement of quality medicine methodological methods methyldopa mobility morbidity mortality nifedipine outcome overall pain Parkinson's disease performance physical function placebo population problems propranolol psychiatric psychological psychometric psychosocial QALY questionnaire questions reliability respiratory response rheumatoid arthritis Rosser scale self-administered sensitivity Sickness Impact Profile side-effects SIP score specific standard standard gamble statistical surgery symptoms Table testing therapy treatment validity valuation verapamil weights well-years